GH ADMINISTRATION ON CARDIOVASCULAR RISK IN SUBJECTS W/GROWTH HORMONE DEFICENCY

GH 给药对生长激素缺乏症患者心血管风险的影响

• 批准号: 7607074
• 负责人: ANNE KLIBANSKI
• 金额: $ 1.67万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607074
• 关键词: Acromegaly; Body Composition; Cardiac; Cardiovascular Diseases; Cardiovascular system; Caring; Cause of Death; Computer Retrieval of Information on Scientific Projects Database; Cross-Sectional Studies; Funding; Grant; Hormone replacement therapy; Institution; Morbidity - disease rate; Patients; Physiological; Pituitary Neoplasms; Population; Quality of life; Research; Research Personnel; Resources; Risk Marker; Somatotrophin increased; Somatotropin; Source; Standards of Weights and Measures; Subgroup; Syndrome; United States National Institutes of Health; Woman; attributable mortality; cardiovascular risk factor; growth hormone deficiency; hormone therapy; men; mortality

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. With the accumulation of evidence on the beneficial effects of GH replacement, this therapy is becoming standard of care in all subjects with GH deficiency (GHD), except in this acromegaly subgroup where GH has been traditionally withheld. The GHD syndrome is manifested by an increase in cardiovascular risk, which is potentially reversible with GH therapy. Cardiovascular disease is the leading cause of death in acromegalics. Although cure of acromegaly is associated with a reduction in mortality attributable to GH excess, GHD may be a contributing factor to cardiovascular morbidity and mortality in this group of patients, as it is in patients with other pituitary tumors. The aim of the study is to evaluate the effects of physiologic growth hormone (GH) replacement on cardiovascular risk markers, cardiac autonomic function, arterial distensibility, body composition, and quality of life in men and women with GH deficiency following treatment of acromegaly. We will compare GH sufficient with GH deficient cured acromegalics in a cross-sectional study. We hypothesize that this population will represent a newly identified group of patients for whom GH replacement will be of benefit.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 随着有关生长激素替代疗法有益效果的证据的积累，这种疗法正在成为所有生长激素缺乏症(GHD)受试者的标准治疗方法，除了传统上不使用生长激素的肢端肥大症患者。GHD综合征的表现是心血管风险增加，这可能是生长激素治疗可逆的。心血管疾病是肢端肥大症的主要死亡原因。虽然肢端肥大症的治愈与GH过量导致的死亡率降低有关，但GHD可能是这类患者心血管发病率和死亡率的一个促成因素，就像在其他脑垂体瘤患者中一样。 本研究的目的是评估生理性生长激素(GH)替代治疗对肢端肥大症患者GH缺乏症患者心血管危险指标、心脏自主神经功能、动脉扩张性、体成分和生活质量的影响。我们将在一项横断面研究中比较GH充足和GH不足治愈的肢端肥大症。我们假设，这一人群将代表一组新确定的患者，生长激素替代治疗将对他们有利。